This trial also showed that high MMP2 and low MMP9 serum levels at baseline were associated with better survival outcomes in patients with HER2+ IBC who received neoadjuvant chemotherapy that included bevacizumab and trastuzumab [114]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.